BetterLife Pharma Inc. (CSE: BETR) announced on November 17, 2026 that new preclinical research partially supported by the company was presented at Neuroscience 2026 in Washington, D.C. The study, conducted by Carleton University researchers, found that BETR-001 — a non-hallucinogenic LSD derivative — produced brain-cell gene expression changes associated with neuroplasticity that broadly overlapped with those observed following LSD treatment. The findings provide additional scientific rationale for BetterLife's planned clinical development program targeting chronic cluster headache and chronic migraine.
Key Points
- BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF / FRA: NPAU) is a Vancouver-based biotechnology company developing BETR-001 for chronic headache disorders.
- Preclinical research presented at Neuroscience 2026 found BETR-001 produced neuroplasticity-related gene expression changes overlapping with LSD despite a non-hallucinogenic behavioural profile.
- The company plans to submit an Investigational New Drug application in Q1 2027 and initiate clinical development during that year.
- Investors may be watching whether these preclinical findings support the company's IND filing timeline and overall BETR-001 development program.
Carleton University Study Uses Single-Nucleus RNA Sequencing to Compare BETR-001 and LSD
The study used single-nucleus RNA sequencing to measure gene activity in individual brain cell nuclei from the prefrontal and cingulate cortex of adult male and female mice treated with either BETR-001 or LSD. Researchers identified overlapping gene expression changes linked to neuroplasticity, stress-hormone signalling, synaptic scaffolding, and dendritic spine remodelling. The findings also included gene expression signatures associated with trafficking of the BDNF receptor TrkB, a pathway involved in synaptic plasticity. The scale of the gene expression response was described as substantial in both sexes, though many specific genes affected differed between male and female mice, particularly following BETR-001 treatment.
Non-Hallucinogenic Profile of BETR-001 Central to BetterLife's Development Rationale
BETR-001 is the R:R stereoisomer of 2-bromo-lysergic acid diethylamide (2-Br-LSD) and has demonstrated a non-hallucinogenic behavioural profile in prior mouse studies, distinguishing it from classical psychedelics. BetterLife holds a granted U.S. composition-of-matter patent covering BETR-001. The company's CEO Ahmad Doroudian stated in the release that the ability to engage neuroplasticity-related molecular pathways without hallucinogenic effects is central to their development approach, and that this research adds to understanding of the mechanisms the company is seeking to harness for patients with chronic headache disorders.
IND Application Planned for Q1 2027 as BETR-001 Advances Toward Clinical Stage
BetterLife is advancing BETR-001 toward a planned Investigational New Drug application in the first quarter of 2027, with the intention to initiate clinical development during that year. BETR-001 remains an investigational product and has not been approved by any regulatory authority, including the U.S. Food and Drug Administration or Health Canada. The company notes that rigorous scientific research and clinical trials are required before any efficacy claims can be established, and that there is no assurance the compound can diagnose, treat, cure, or prevent any disease or condition.




Please wait processing your request...